Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis

People with CF are prone to airway bacterial infection and experience pulmonary exacerbations (PEx), periods of acute increases in respiratory signs and symptoms often coupled with an acute lung function drop, throughout their lives. [1,2] PEx are considered important clinical events; [1-3] guidelines recommend treatment with increased airway clearance, antimicrobial therapy, and nutritional and psychosocial support, [4-5] with antimicrobials chosen by in vitro antimicrobial susceptibility testing (AST) of patient bacterial isolates.

Source: Journal of Cystic Fibrosis - June 3, 2020 Category: Respiratory Medicine Authors: Donald R. VanDevanter, Sonya L. Heltshe, Jay B. Hilliard, Michael W. Konstan Source Type: research